|View printer-friendly version|
|April 25, 2006 1:38 p.m.|
|Teva Receives First FDA Approval for Generic Pravachol®; Appellate Court Denies Apotex Request for Injunctive Relief|
Jerusalem, Israel, April 25, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Bristol-Myers Squibb's Pravachol® (Pravastatin Sodium) Tablets, 10 mg, 20 mg and 40 mg. Shipment of these products will begin immediately. As the first company to file an ANDA containing a paragraph IV certification for these strengths, Teva has been awarded 180 days of marketing exclusivity.